DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response

被引:31
作者
Bodell, William J. [1 ,2 ]
机构
[1] Contrast Therapeut, Richmond, CA 94806 USA
[2] Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, Lab Mol Therapeut, San Francisco, CA 94143 USA
关键词
BCNU; DNA adducts; Drug delivery; Molecular dosimeter; Therapeutic response; RECURRENT MALIGNANT GLIOMA; CONVECTION-ENHANCED DELIVERY; RECURSIVE PARTITIONING ANALYSIS; NEWLY-DIAGNOSED GLIOBLASTOMA; DRUG-DELIVERY; ONCOLOGY-GROUP; BLOOD-BRAIN; CROSS-LINK; II TRIAL; CHEMOTHERAPY;
D O I
10.1007/s11060-008-9715-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study has investigated if individual DNA adducts formed in human glioma cells treated with (3)H-1-(2-chloroethyl)-1-nitrosourea ((3)H-CNU) could be used as molecular dosimeters of response after CENU treatment. The levels of individual DNA alkylation products were compared with the induction of cytotoxicity in six human glioma cell lines after treatment with (3)H-CNU. The levels of seven DNA adducts N7-(2-hydroxyethyl)guanine, (N7-HOEtG); N7-(2-chloroethyl)guanine, (N7-ClEtG); 1,2-[diguan-7-yl]-ethane, (N7-bis-G); N1-(2-hydroxyethyl)-2-deoxyguanosine, N1-HOEtdG; 1-[N1-2-deoxyguanosinyl], 2-[N3-2-deoxycytidyl]-ethane, dG-dC; O(6)-(2-hydroxyethyl)-2-deoxyguanosine, O(6)-HOEtdG and phosphotriesters (PTE), were quantified in each of the cell lines following treatment with (3)H-CNU. The levels of N7-HOEtG, N7-ClEtG; O(6)-HOEtdG and PTE were not significantly different in the glioma lines and their levels were not associated with the induction of cytotoxicity by CNU treatment. The levels of N7-bis-G, N1-HOEtdG and dG-dC crosslink were significantly lower in both SF-188 and SF-763 cell lines compared to their levels in U87MG, U251MG and SF-126. There was a significant correlation between CNU LD(10) values and with the levels of levels of N7-bis-G and N1-HOEtdG (R = -0.91, P = 0.01) and dG-dC crosslink (R = -0.94, P = 0.005) in the glioma cell lines. Pretreatment of SF-188 cells with varying concentrations of MNU prior to CNU treatment resulted in no change in the levels of N7-HOEtG, N7-ClEtG; O(6)-HOEtdG and PTE and a dose dependent increase in the levels of N7-bis-G, N1-HOEtdG and dG-dC crosslink. Taken together, these results suggest that the levels of the N7-bis-G, N1-HOEtdG and dG-dC crosslink could be used as molecular dosimeters of therapeutic response following treatment with BCNU or related CENU.
引用
收藏
页码:257 / 264
页数:8
相关论文
共 41 条
  • [11] A gynecologic oncology group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy
    Darcy, Kathleen M.
    Tian, Chunqiao
    Reed, Eddie
    [J]. CANCER RESEARCH, 2007, 67 (09) : 4474 - 4481
  • [12] The blood-brain barrier and cancer:: Transporters, treatment, and Trojan horses
    Deeken, John F.
    Loescher, Wolfgang
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (06) : 1663 - 1674
  • [13] MGMT: Its role in cancer aetiology and cancer therapeutics
    Gerson, SL
    [J]. NATURE REVIEWS CANCER, 2004, 4 (04) : 296 - 307
  • [14] Groothuis DR, 2000, NEURO-ONCOLOGY, V2, P45, DOI 10.1093/neuonc/2.1.45
  • [15] Advances in the biology of astrocytomas
    Guha, A
    Mukherjee, J
    [J]. CURRENT OPINION IN NEUROLOGY, 2004, 17 (06) : 655 - 662
  • [16] Stereotactic injection of DTI-015 into recurrent malignant gliomas: Phase I/II trial
    Hassenbusch, SJ
    Nardone, EM
    Levin, VA
    Leeds, N
    Pietronigro, D
    [J]. NEOPLASIA, 2003, 5 (01): : 9 - 16
  • [17] Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
    Herrlinger, Ulrich
    Rieger, Johannes
    Koch, Dorothee
    Loeser, Simon
    Blaschke, Britta
    Kortmann, Rolf-Dieter
    Steinbach, Joachim P.
    Hundsberger, Thomas
    Wick, Wolfgang
    Meyermann, Richard
    Tan, Ta-Chih
    Sommer, Clemens
    Bamberg, Michael
    Reifenberger, Guido
    Weller, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4412 - 4417
  • [18] Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT)
    Hoebers, Frank J. P.
    Pluim, Dick
    Verheij, Marcel
    Balm, Alfons J. M.
    Bartelink, Harry
    Schellens, Jan H. M.
    Begg, Adrian C.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) : 750 - 756
  • [19] Long-term survival with glioblastoma multiforme
    Krex, Dietmar
    Klink, Barbara
    Hartmann, Christian
    von Deimling, Andreas
    Pietsch, Torsten
    Simon, Matthias
    Sabel, Michael
    Steinbach, Joachim P.
    Heese, Oliver
    Reifenberger, Guido
    Weller, Michael
    Schackert, Gabriele
    [J]. BRAIN, 2007, 130 : 2596 - 2606
  • [20] Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group
    Kunwar, Sandeep
    Prados, Michael D.
    Chang, Susan M.
    Berger, Mitchel S.
    Lang, Frederick F.
    Piepmeier, Joseph M.
    Sampson, John H.
    Ram, Zvi
    Gutin, Philip H.
    Gibbons, Robert D.
    Aldape, Kenneth D.
    Croteau, David J.
    Sherman, Jeffrey W.
    Puri, Raj K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) : 837 - 844